加州监禁患者接受阿片类药物治疗期间丙肝再感染病例对照研究
该研究在加州州立监狱中接受丙肝治疗并达到持续病毒学应答、且在持续病毒学应答前开始阿片类药物治疗的监禁人群中,开展病例对照研究。50例再感染病例与108例对照相比,丙肝再感染独立关联于注射吸毒、不洁纹身、甲基苯丙胺使用、较年轻年龄及较低的美沙酮/丁丙诺啡依从性。即使完全依从阿片类药物治疗带来70%保护效应,患者仍报告持续风险行为。
要点
- 注射吸毒与不洁纹身均使丙肝再感染风险升高约3.4倍。
- 甲基苯丙胺使用使再感染风险升高约2.5倍。
- 完全依从阿片类药物治疗对丙肝再感染有70%保护效应。
核心结论
- 即使完全依从阿片类药物治疗带来70%保护效应,患者仍报告持续风险行为。
- 注射吸毒、甲基苯丙胺使用和不洁纹身也增加其他血源性或皮肤软组织感染及过量的风险。
研究设计与样本
- 病例对照研究,对加州州立监狱中启动丙肝治疗、达到持续病毒学应答且在持续病毒学应答前开始阿片类药物治疗的监禁者健康记录进行二次数据分析。
- 病例为1年内再感染,对照为1年时仍丙肝阴性;共50例病例和108例对照。
主要发现
- 合格受试者主要为男性(96.2%)、西班牙裔/拉丁裔(62.7%)或白人(29.1%),中位年龄36岁(范围23-60岁)。
- 丙肝再感染独立关联于注射吸毒(aOR=3.4;95%CI 1.3-8.5)。
- 丙肝再感染独立关联于不洁纹身(aOR=3.4;95%CI 1.2-9.9)。
- 丙肝再感染独立关联于甲基苯丙胺使用(aOR=2.5;95%CI 1.0-6.1)。
临床怎么用
- 改善健康结局可通过整合加强阿片类药物治疗监测与扩大减害措施(包括注射器服务和针对兴奋剂使用障碍的 contingency management)来实现。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Incarcerated people are disproportionately burdened with hepatitis C virus (HCV) infection and experience elevated risk of reinfection following treatment. Medication for opioid use disorder (MOUD) has been shown to reduce, but not eliminate, reinfection. Research is lacking on patient-level factors associated with HCV reinfection in incarcerated populations in the United States receiving MOUD. METHODS: We conducted a case-control study from secondary data analysis of health records among people incarcerated in California state prisons who initiated HCV treatment, achieved sustained virologic response, and began MOUD before sustained virologic response. Case-patients were reinfected within 1 year; controls remained HCV-negative at 1 year. RESULTS: Eligible subjects (50 cases; 108 controls) were predominantly male (96.2%), Hispanic/Latinx (62.7%) or White (29.1%), and median age 36 (range, 23-60) years. HCV reinfection was independently associated with injection drug use (adjusted odds ratio [aOR] = 3.4; 95% confidence interval [CI], 1.3-8.5), unsterile tattooing (aOR = 3.4; 95% CI, 1.2-9.9), methamphetamine use (aOR = 2.5; 95% CI, 1.0-6.1), younger age (aOR = 0.7; 95% CI, .5-.9; units = 5 years), and lower adherence to adequately dosed (≥16 mg/day) buprenorphine (aOR = 0.7; 95% CI, .6-1.0; units = 0.25, aOR = 0.3; 95% CI, .1-.9; units = 1.0). CONCLUSIONS: Even with complete MOUD adherence, conferring a 70% protective effect for HCV reinfection, patients reported ongoing risk behaviors. Injection drug use, methamphetamine use, and unsterile tattooing also increase the risk of other bloodborne or skin and soft tissue infections and overdose. Improved health outcomes could be achieved with integrating enhanced monitoring of MOUD with expanded harm reduction including syringe services and contingency management for treatment of stimulant use disorders.
引用
- Shemuel J, Krawiec AT, Kalauokalani D, et al. A Case-Control Study of Hepatitis C Virus Reinfection in Incarcerated Patients in California Receiving Medication for Opioid Use Disorder. Clin Infect Dis. 2025. PMID: 40231397. doi:10.1093/cid/ciaf192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。